{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:17:39Z","timestamp":1763572659409,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug. Discov."],"abstract":"<jats:p>Invasive candidiasis remains a significant health concern, as it is associated with a high mortality risk. In addition, the risk of infection is significantly elevated in immunocompromised patients such as those with HIV, cancer, or those taking imcmunosuppressive drugs as a result of organ transplantation. The majority of these cases are caused by <jats:italic>C. albicans<\/jats:italic>, and <jats:italic>C. glabrata<\/jats:italic> is the second most common cause. These infections are typically treated using approved antifungal agents, but the rise of drug-resistant fungi is a serious concern. As part of our on-going effort to identify novel antifungal agents, we have studied the <jats:italic>in vitro<\/jats:italic> antifungal properties of a series of sulfonamide analogs of (2S, 4R)-Ketoconazole. Herein we report on the <jats:italic>in vitro<\/jats:italic> activity against the key fungal pathogens <jats:italic>C. albicans<\/jats:italic>, and <jats:italic>C. glabrata<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fddsv.2022.1000827","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:12:55Z","timestamp":1661757175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs"],"prefix":"10.3389","volume":"2","author":[{"given":"Benjamin E.","family":"Blass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumant","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishabh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"B1","first-page":"3","article-title":"Dioxolan-2-ylmethyl)-1H-1, 2, 4-triazoles, US patent application US76426377A","volume":"1","author":"Backx","year":"1979","journal-title":"U.S. Pat. Trademark Office"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1016\/j.bmcl.2016.10.016","article-title":"Design, synthesis, and evaluation of (2S, 4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome","volume":"26","author":"Blass","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J. Fungi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1128\/AAC.00747-06","article-title":"Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae","volume":"50","author":"Chau","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"volume-title":"Approved standard","year":"2017","article-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","key":"B5"},{"unstructured":"FDA websie\n            FDA websie\n          2022","key":"B6"},{"key":"B7","first-page":"1260","volume-title":"Drug used to treat fungal infection\u201d in Foye\u2019s Principles of Medicinal Chemistry","author":"Griffith","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/jac\/dkv445","article-title":"Drug resistance mechanisms and their regulation in non-albicans Candida species","volume":"71","author":"Kolaczkowska","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the development of azole derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","article-title":"Invasive candidiasis","volume":"30","author":"McCarty","year":"2016","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B12","doi-asserted-by":"publisher","first-page":"670862","DOI":"10.3389\/fphar.2021.670862","article-title":"A review of CYP3A drug-drug interaction studies: Practical guidelines for patients using targeted oral anticancer drugs","volume":"12","author":"Molenaar-Kuijsten","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"140206","DOI":"10.1016\/j.bbapap.2019.02.008","article-title":"Fungal lanosterol 14\u03b1-demethylase: A target for next-generation antifungal design","volume":"3","author":"Monk","year":"2020","journal-title":"Biochim. Biophys. Acta. Proteins Proteom."},{"key":"B14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: Challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1021\/jm00093a015","article-title":"Stereoisomers of ketoconazole: Preparation and biological activity","volume":"35","author":"Rotstein","year":"1992","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1128\/AAC.43.11.2753","article-title":"The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents","volume":"43","author":"Sanglard","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.fgb.2015.06.001","article-title":"Genotype-phenotype complexity of the TR46\/Y121F\/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus","volume":"82","author":"Snelders","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.fgb.2011.08.002","article-title":"The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance","volume":"48","author":"Snelders","year":"2011","journal-title":"Fungal Genet. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/jof4020060","article-title":"Adhesins in Candida glabrata","volume":"4","author":"Timmermans","year":"2018","journal-title":"J. Fungi"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1093\/ofid\/ofy210.374","article-title":"363. National burden of candidemia, United States, 2017","volume":"5","author":"Tsay","year":"2018","journal-title":"Open Forum Infect. Dis."},{"unstructured":"US CDC website","key":"B23"},{"unstructured":"US CDC website","key":"B24"},{"key":"B25","doi-asserted-by":"publisher","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: Data from a large multisite population-based candidemia surveillance program, 2008-2014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1128\/AAC.48.10.3773-3781.2004","article-title":"Azole resistance in Candida glabrata: Coordinate upregulation of multidrug transporters and evidence for a pdr1-like transcription factor","volume":"48","author":"Vermitsky","year":"2004","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Drug Discovery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddsv.2022.1000827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:13:03Z","timestamp":1661757183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddsv.2022.1000827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":26,"alternative-id":["10.3389\/fddsv.2022.1000827"],"URL":"https:\/\/doi.org\/10.3389\/fddsv.2022.1000827","relation":{},"ISSN":["2674-0338"],"issn-type":[{"type":"electronic","value":"2674-0338"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"article-number":"1000827"}}